Abdenour Nabid, MD, associate professor at Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of androgen-deprivation therapy (ADT) to 36 months in men with high-risk, localized prostate cancer.

In the study, 630 patients were evenly randomized to 36 or 18 months of pelvic radiotherapy plus bicalutamide and goserelin. At a median follow-up of 77 months, the study found that both overall survival and disease-specific survival were not statistically different between the two arms.

Treatment with ADT may result in serious adverse events that make a patient's life miserable, Nabid points out. Shortening the duration of treatment could help alleviate some of these side effects and improve quality of life.

A more thorough analysis of quality of life is currently underway looking at patient-reported data from 9638 questionnaires. This analysis will provide further information on the impact of treatment duration on quality of life for men in this study.

View coverage from the 2013 GU Cancers Symposium

Videos

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer. 

Abdenour Nabid, MD

Articles

Dr. Nabid on a Shorter Duration of ADT in Prostate Cancer